Response and Nippon Kayaku to develop PSA (prostate specific antigen) test:
This article was originally published in Clinica
Response Biomedical and Japanese company Nippon Kayaku are to collaborate on developing a prostate cancer test for use on Response's quantitative, point-of-care RAMP diagnostic system. The Vancouver, British Columbia company has signed an agreement with the Japanese partner, based in Tokyo, to make a test for the prostate cancer marker prostate specific antigen (PSA). Nippon Kayaku will fund the development and Japanese regulatory submission of the PSA test and will have sales and distribution rights for the product in Japan. Response reserves rights for other markets. The company has already developed a number of tests for other medical conditions for use on the RAMP assay.
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.